Management
|
|
Anna Ljung, CEO , M.Sc. Econ.
Born 1980. Active in the company since 2006. Anna Ljung has more than 20 years of experience in the pharmaceutical industry, including as CFO of other biotech companies such as Athera Biotechnologies AB and Lipopetide AB and as independent technology licensing consultant. In addition to serving as CEO of Moberg Pharma, she also currently serves as Chair of Biosergen AB and as a Board member of Saniona AB and ADDvise Group AB.
Shareholding: 69 806 shares and 326 528 performance share units that can entitle a maximum of 352 782 shares.
|
 |
Annica Magnusson, Senior Director of Regulatory Affairs Born in 1963. Has worked for the company since 2013. Annica Magnusson is a pharmacist with more than 20 years of experience in international work within the pharmaceutical industry and Regulatory Affairs at AstraZeneca. Annica Mangusson has worked with the development and registration of pharmaceuticals, vaccines and medical devices in the EU, USA, Japan with several markets. Shareholding: 46 646 shares and 195 916 performance share units that can entitle a maximum of 211 668 shares.
|
 |
Mark Beveridge, Vice President Finance Born 1978. B. Com, GradDipCA. Active in the company since 2015. Mark Beveridge has more than 15 years of experience as an advisor in accounting, insurance and auditing, primarily from Crowe Horwath and Visma Services. Mark has also worked as an independent consultant within financial control, transaction consultancy and implementation of business systems. Mark is Board member of Loaded Dice AB. Shareholding: 88 931 shares and 195 916 performance share units that can entitle a maximum of 211 668 shares |
 |
Christina Erixon, Senior Director Product Management Born 1970. Active in the company since 2023. Christina Erixon has more than 20 years of experience of pharmaceutical development, production, regulatory and quality within the pharmaceutical industry. She has held leading positions within the pharmaceutical industry and at regulatory authorities, including roles as manager of clinical trials at the Swedish Medical Products Agency, senior product developer at AstraZeneca, business manager and associate director Pharmaceutical Development at APL, and most recently as the director of Drug Development at SDS Life Science (Cytel Sweden). Christina Erixon is a pharmacist with a doctoral degree in pharmaceutics from Uppsala University Shareholding: 0 shares and 165 916 performance share units that can entitle a maximum of 165 916 shares |
Current shareholding is not automatically updated for the moment. Insiders no longer have obligation to report there shareholding. According to the regulatory requirements, the data shall be updated once a year.